535 Shares in Charles River Laboratories International, Inc. (NYSE:CRL) Purchased by Acadian Asset Management LLC

Acadian Asset Management LLC acquired a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 535 shares of the medical research company’s stock, valued at approximately $110,000.

Several other large investors have also bought and sold shares of CRL. Vanguard Group Inc. lifted its holdings in shares of Charles River Laboratories International by 1.1% during the first quarter. Vanguard Group Inc. now owns 6,046,467 shares of the medical research company’s stock valued at $1,638,290,000 after purchasing an additional 66,161 shares in the last quarter. Clearbridge Investments LLC raised its stake in Charles River Laboratories International by 3.1% during the 1st quarter. Clearbridge Investments LLC now owns 1,513,138 shares of the medical research company’s stock valued at $409,985,000 after buying an additional 45,079 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Charles River Laboratories International by 11.9% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,251,618 shares of the medical research company’s stock valued at $258,559,000 after buying an additional 132,802 shares during the period. Meritage Group LP increased its position in Charles River Laboratories International by 2.3% during the first quarter. Meritage Group LP now owns 1,182,268 shares of the medical research company’s stock valued at $320,336,000 after acquiring an additional 26,892 shares during the last quarter. Finally, Earnest Partners LLC lifted its holdings in Charles River Laboratories International by 0.5% in the first quarter. Earnest Partners LLC now owns 893,761 shares of the medical research company’s stock valued at $242,165,000 after acquiring an additional 4,393 shares during the period. 98.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CRL has been the subject of a number of recent research reports. TD Cowen cut their price target on Charles River Laboratories International from $228.00 to $203.00 and set a “hold” rating for the company in a research note on Monday, August 12th. Mizuho assumed coverage on shares of Charles River Laboratories International in a research note on Friday, June 7th. They set a “neutral” rating and a $235.00 price target on the stock. Argus reaffirmed a “hold” rating on shares of Charles River Laboratories International in a report on Friday, June 28th. Barclays cut their price target on Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating for the company in a report on Thursday, August 8th. Finally, The Goldman Sachs Group cut their price objective on Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating for the company in a research note on Thursday, August 8th. Ten analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, Charles River Laboratories International currently has a consensus rating of “Hold” and an average price target of $230.93.

Charles River Laboratories International Stock Down 1.8 %

NYSE CRL opened at $205.79 on Friday. The stock has a 50 day moving average price of $209.34 and a 200-day moving average price of $223.80. Charles River Laboratories International, Inc. has a one year low of $161.65 and a one year high of $275.00. The company has a market capitalization of $10.60 billion, a P/E ratio of 24.21, a P/E/G ratio of 3.89 and a beta of 1.36. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.21 and a current ratio of 1.58.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, August 7th. The medical research company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.39 by $0.41. The firm had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.03 billion. Charles River Laboratories International had a net margin of 10.83% and a return on equity of 14.96%. As a group, equities analysts predict that Charles River Laboratories International, Inc. will post 10.01 EPS for the current fiscal year.

Charles River Laboratories International announced that its Board of Directors has initiated a share repurchase program on Wednesday, August 7th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 9.6% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s leadership believes its shares are undervalued.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).